ストックスクリーナーアプリを入手
109.64
4.28%
-4.90
プレマーケット:
109.64
Gilead Sciences Inc (GILD) 最新ニュース
Leerink Partners raises PT on Gilead, citing HIV treatments prospects - TradingView
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc.GILD - PR Newswire
Gilead sees Q2 EPS hit from IPR&D expenses - Seeking Alpha
Gilead Sciences Inc. stock underperforms Friday when compared to competitors - MarketWatch
Guardant Health, Gilead Sciences, Inspire Medical Systems, Enovis, and AMN Healthcare Services Stocks Trade Down, What You Need To Know - Yahoo Finance
BriaCell Says Bria-IMT Outperforms Trodelvy in Phase 2 Metastatic Breast Cancer Trial - MarketScreener
Time To Grow PFL Fanbase, Revenue: CEO John Martin - MarketScreener
Gilead Sciences, Inc. (GILD): A Bull Case Theory - Yahoo
Gilead Expands Global Access to Lenacapavir With New HIV Prevention Partnership - Contagion Live
Gilead & Global Fund Partner for HIV Prevention - Contract Pharma
Here's Why Gilead Sciences (GILD) is a Strong Momentum Stock - Yahoo
Gilead to Provide New HIV Drug to Lower-Income Countries Through Novel Philanthropic Partnership - BioSpace
Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know - Nasdaq
Gilead Sciences (NasdaqGS:GILD) Partners With Global Fund To Supply HIV Prevention Drug - Yahoo Finance
Gilead's Lenacapavir Plan Faces Global Hurdles As It Commits To No-Profit Access for 2 Million - Benzinga
Gilead in pact to speed up access to new HIV therapy in low-income nations - Seeking Alpha
Gilead signs lenacapavir access deal; Arvinas CEO to step down - BioPharma Dive
Gilead, Global Fund finalize plan to supply HIV prevention drug to poor countries - Reuters
Gilead Sciences, Inc. (GILD) Reports Advances in HIV Treatment with Phase 2/3 Clinical Trial Update - Yahoo Finance
Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term - Yahoo Finance
Gilead Finalizes Agreement With the Global Fund to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries - Business Wire
Gilead Sciences Rallies 27.2% in Six Months: Buy or Sell the Stock? - Nasdaq
Has Gilead Sciences (GILD) Outpaced Other Medical Stocks This Year? - Nasdaq
Gilead Sciences Rallies 27.2% In Six Months: Buy Or Sell The Stock? - Barchart.com
August 22nd Options Now Available For Gilead Sciences (GILD) - Nasdaq
Gilead Sciences, Inc. proudly Supports Unite for HER's Metastatic Breast Cancer Sustainer Program - 24-7 Press Release Newswire
Gilead SciencesBorn With HIV in the 80s: Kim’s Story of Growing Up as a Dandelion - CSRwire
Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders - Business Wire
From the Margins - Gilead Sciences
Looking Back to the Future: Gilead’s Long-Standing Commitment to Help End the HIV Epidemic - Gilead Sciences
FDA Approves Gilead's Twice-Yearly Shot for HIV Prevention - Yahoo Finance
Gilead Sciences Lands First FDA Approval of a Twice-a-Year HIV PrEP Drug - MedCity News
US FDA approves Gilead's twice-yearly injection for HIV prevention - Deccan Herald
US approves Gilead’s twice-yearly injection to prevent HIV - The Malaysian Reserve
US approves Gilead's twice-yearly injection to prevent HIV - El Paso Inc.
The world's only twice-a-year shot to prevent HIV could stop transmission — if people can get it - Shelton Herald
Gilead Sciences facility video - KTIV
HIV prevention drug lenacapavir approved by FDA as twice-yearly injection - CBS News
FDA approves Gilead's twice-yearly HIV prevention shot - FirstWord Pharma
Gilead Wins Historic Approval for Twice-Yearly HIV Drug - BioSpace
HIV advance: Twice-yearly shot to prevent infection - NZ Herald
Cautious Optimism for Gilead Sciences Amid Yeztugo’s Market Challenges - TipRanks
Gilead's twice-yearly PrEP drug is cleared by FDA - pharmaphorum
FDA approves twice-yearly shot of Gilead drug for HIV prevention - BioPharma Dive
Gilead's HIV Prevention Drug Is 99.9% Effective. Could Politics Derail It? - Investor's Business Daily
US Approves Gilead's Twice-yearly Injection To Prevent HIV - Barron's
FDA Approves Gilead’s Twice-Yearly Injection for HIV Prevention - The Well News
FDA approves 6-month HIV prevention shot - The Hill
Gilead's (GILD) HIV Treatment Yeztugo Gains FDA Approval, Market Potential Expands | GILD Stock News - GuruFocus
FDA Approval Boosts Gilead's (GILD) Prospects in HIV Prevention | GILD Stock News - GuruFocus
Gilead Sciences stock steady as FDA approves twice-yearly HIV prevention - Investing.com UK
Mizuho says Gilead Yeztugo label looks clean - TipRanks
Gilead Sciences (GILD) Gains FDA Nod for HIV Prevention Drug - GuruFocus
FDA Approves Gilead’s HIV Shot. It Works 99.9% of the Time. - Barron's
Gilead Sciences’ Yeztugo Approval and Market Expansion Drive Buy Rating - TipRanks
FDA approves powerful HIV prevention drug: What to know about Yeztugo - NBC News
FDA approves the world’s only twice-a-year shot to prevent HIV - mypanhandle.com
FDA Approves Gilead’s Twice-Yearly Injectable Lenacapavir (Yeztugo) for HIV Prevention - ContagionLive
Gilead’s twice-yearly PrEP injection wins FDA approval, analysts see solid launch ahead - Proactive financial news
Gilead Sciences' HIV Prevention Drug Yeztugo Receives FDA Approval - MarketScreener
Gilead (GILD) Gains FDA Approval for Unique HIV Prevention Drug Yeztugo | GILD Stock News - GuruFocus
Gilead announces FDA approves Yeztugo as twice-a-year HIV prevention option - TipRanks
Gilead’s Twice-a-Year HIV Prevention Shot Wins US FDA Approval - Bloomberg.com
Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection - marketscreener.com
Gilead's (GILD) Lenacapavir Advances as HIV Prevention Treatment - GuruFocus
Gilead (GILD) Gains FDA Approval for HIV Prevention Injection | - GuruFocus
Gilead’s twice-yearly HIV prevention shot gets FDA approval - Investing.com Australia
US FDA approves Gilead’s twice-yearly injection for HIV prevention By Reuters - Investing.com
Gilead’s twice-yearly HIV prevention shot gets FDA approval By Investing.com - Investing.com Canada
0.50%
大文字化:
|
ボリューム (24 時間):